Antiviral therapy for chronic hepatitis B is currently available in the form of interferon and nucleoside analogs. Although nucleoside analogs are easy to use and can better inhibit HBV replication for a certain period of time, thus inhibiting the progression of chronic hepatitis B. However, due to its low HbeAg seroconversion rate, short-term treatment discontinuation often leads to the recurrence of viral replication, and prolonged application can produce viral drug-resistant variants and other defects, interferon is still the choice of antiviral treatment of chronic hepatitis B has some advantages of drugs , especially PEG-IFN. The goal of chronic hepatitis C treatment is to obtain a sustained viral response. Interferon antiviral therapy in chronic hepatitis C is different from that against chronic hepatitis B virus because HCV replicates within the cytoplasm and interferon-induced intracellular antiviral proteins mechanism of viral replication is stronger than that of hepatitis B virus, but viral clearance is still dependent on the inhibition of cellular viral replication and the clearance of virus-infected cells by specific immunity. Only intracellular antiviral effect and insufficient cellular immunity is similar to the nucleoside analogs for chronic hepatitis B, and relapse occurs after discontinuation of the drug, while only cellular immune response without inhibition of intracellular viral replication, replicating viruses can be re-infected with other cells, which makes it very difficult to clear the virus-infected cells, so interferon must be combined with ribavirin in antiviral therapy for chronic hepatitis C in the absence of contraindications. Ribavirin, because ribavirin enhances cellular immunity and improves sustained viral response by decreasing the rate of relapse in therapy, PEG-IFN combined with ribavirin is the current standard of care in antiviral therapy treatment for chronic hepatitis C.